As we continue to develop potential therapies, the FDA has recently begun a national effort to expand access to convalescent plasma donated from the blood of those who have recovered from the virus. The blood of these donors contains antibodies that can potentially reduce the severity of the illness in those who are sick--and frankly, those that are very sick. Nearly 3,000 patients are now enrolled in the Expanded Access Program, receiving transfusions nationwide.